ArticleJournal of virology1998
Packaging cells based on inducible gene amplification for the production of adeno-associated virus vectors.
Article in Journal of virology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 111 citations in OpenAlex.
- Inducible HEK293 AAV packaging cell lines expressing Rep proteins.Molecular therapy. Methods & clinical development · 2023Article
- The effects of polymorphisms on human gene targeting.Nucleic acids research · 2014Article
- AAV-mediated gene targeting methods for human cells.Nature protocols · 2011Article
- Gene therapy of mdx mice with large truncated dystrophins generated by recombination using rAAV6.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Article
- Engineering of human pluripotent stem cells by AAV-mediated gene targeting.Molecular therapy : the journal of the American Society of Gene Therapy · 2010Article
- Gene targeting of mutant COL1A2 alleles in mesenchymal stem cells from individuals with osteogenesis imperfecta.Molecular therapy : the journal of the American Society of Gene Therapy · 2008Article
- cis effects in adeno-associated virus type 2 replication.Journal of virology · 2007Article
- Current issues in adeno-associated viral vector production.Gene therapy · 2005Review
- Evaluation of a Serum-free Medium for the Production of rAAV-2 using HeLa Derived Producer Cells.Cytotechnology · 2005Article
- Large-scale analysis of adeno-associated virus vector integration sites in normal human cells.Journal of virology · 2005Article
- Separate control of Rep and Cap expression using mutant and wild-type loxP sequences and improved packaging system for adeno-associated virus vector production.Molecular biotechnology · 2004Article
- Targeted correction of single-base-pair mutations with adeno-associated virus vectors under nonselective conditions.Journal of virology · 2004Article
- Chromosomal integration and homologous gene targeting by replication-incompetent vectors based on the autonomous parvovirus minute virus of mice.Journal of virology · 2003Article
- Characterization of entry mechanisms of human herpesvirus 8 by using an Rta-dependent reporter cell line.Journal of virology · 2003Article
- Human gene targeting by adeno-associated virus vectors is enhanced by DNA double-strand breaks.Molecular and cellular biology · 2003Article
- A novel gene expression control system and its use in stable, high-titer 293 cell-based adeno-associated virus packaging cell lines.Journal of virology · 2002Article
- Article
- Feasibility of generating adeno-associated virus packaging cell lines containing inducible adenovirus helper genes.Journal of virology · 2002Article
- A novel MVMp-based vector system specifically designed to reduce the risk of replication-competent virus generation by homologous recombination.Gene therapy · 2001Article
- Characterization of adenovirus-induced inverted terminal repeat-independent amplification of integrated adeno-associated virus rep-cap sequences.Journal of virology · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although vectors based on adeno-associated virus (AAV) offer several unique advantages, their usage has been hampered by the difficulties encountered in vector production. In this report, we describe a new AAV packaging system based on inducible amplification of integrated helper and vector constructs containing the simian virus 40 (SV40) replication origin. The packaging and producer cell lines developed express SV40 T antigen under the control of the reverse tetracycline transactivator system, which allows inducible amplification of chromosomal loci linked to the SV40 origin. Culturing these cells in the presence of doxycycline followed by adenovirus infection resulted in helper and vector gene amplification as well as higher vector titers. Clonal producer cell lines generated vector titers that were 10 times higher than those obtained by standard methods, with approximately 10(4) vector particles produced per cell. These stocks were free of detectable replication-competent virus. The lack of a transfection step combined with the reproducibility of stable producer lines makes this packaging method ideally suited for the large-scale production of vector stocks for human gene therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.